🌍 Society & Frontier risk-on · 6–18 months
A what‑if from the future

What if Pharma 'voluntary' direct-to-patient pricing blunts MFN threat?

Lilly and Pfizer launch cash direct-to-consumer pricing to pre-empt MFN, partially defusing the political risk and prompting a relief rally in the drug names.

21%
our model probability
over 6–18 months
prediction markets — wisdom of the crowd
loading live odds…
Empirically anchored 21% · 90% range 0–48% · 13 analogues · measured class biotech 24% in 18 mo · 3% held back for the unknown
how we built this number — every step
Measured class rate — biotech ≈0.1843/yr → 24% in 18 mo24%
Analyst prior · editorial share 100% of the class34%
Pooled · weight 68%22%
Crowd — no liquid market
Reserve 3% · no extremizing (×1.0)22%
Published21%

The class rate is measured from our dated, sourced event library (decade-normalized Poisson — the full table is public at base_rates.json). The variant’s share within its class is the analyst’s editorial call, published so you can audit it. A wider range means thinner precedent. Full recipe: methodology · scored at Reality Check.

The butterfly cascade

How this trigger trickles across markets, left → right — the root shock, its first‑order moves, then the ripple effects. Drag any node; tap a market for its real price history.

Resolution timeline — how this probability is moving

Our model's odds (gold) over time vs the crowd's (Polymarket, blue), from the past toward the 6–18 months horizon. Each dot is a real macro event that nudged the probability — green pushed it up, red pushed it down. Tap a dot for the source. The gold path is an illustrative reconstruction anchored to today's estimate — real dated events, not a live re-estimate history.

loading the timeline…

What it would mean

If this plays out, it is a risk-on shock. Lilly and Pfizer launch cash direct-to-consumer pricing to pre-empt MFN, partially defusing the political risk and prompting a relief rally in the drug names. The trigger decomposes into signed root‑shocks — Biotech breakthrough ▲ · Consumer spending ▲ · Risk appetite ▲ — which propagate through our causal graph to the markets below.

If it happens — the markets it would move

Biggest moves first. Projected moves are cascade-model priors; hist A–B% = what comparable past events actually did (measured abnormal returns), and model prior · unmeasured marks markets with no analogue backing yet. Tap any market for its price history.

MarketClassProjected move
1Solana SOLon Hyperliquid 📈 chartCrypto▲ +0.6%
hist -9.03–+4.84% · other way -4.42% (n=11)
2Hyperliquid (HYPE) HYPEon HyperliquidCrypto▲ +0.5%
model prior · unmeasured
3Ether ETHon Hyperliquid 📈 chartCrypto▲ +0.4%
hist -2.03–+2.23% · other way -5.47% (n=12)
4Nasdaq 100 NDXon Hyperliquid 📈 chartIndex▲ +0.4%
hist +0.06–+0.48% · other way +0.36% (n=12)
5MicroStrategy MSTRon Hyperliquid 📈 chartEquity▲ +0.4%
hist -9.24–+14.28% · other way +11.19% (n=12)
6Bitcoin BTCon Hyperliquid 📈 chartCrypto▲ +0.3%
hist -4.21–+7.04% · other way -1.09% (n=12)
7Volatility (VIX) VIXon Hyperliquid 📈 chartVol▼ -0.3%
hist -2.08–+2.28% · other way +9.33% (n=12)
8S&P 500 SPXon Hyperliquid 📈 chartIndex▲ +0.2%
hist -0.12–+0.53% · other way -2.38% (n=12)
9Tech sector XLK 📈 chartEquity▲ +0.2%
hist -0.4–+0.87% · other way +0.25% (n=12)
10Coinbase COINon Hyperliquid 📈 chartEquity▲ +0.2%
hist -2.12–+2.6% · other way +6.65% (n=11)
11Semiconductors SMHon Hyperliquid 📈 chartEquity▲ +0.2%
hist -0.44–+0.91% · other way +0.19% (n=12)

Probable recommendation

If the scenario above plays out, the probable cross‑asset positioning → a scenario‑conditional read, not personalized investment advice
For a common-man portfolio: A typical stock-heavy portfolio should benefit. Stay invested; you can lean modestly into the beneficiaries below.
Also moves (not yet on Hyperliquid): Tech sector +0.2%

Historical precedent — what analogous events actually did

Across 13 analogous events (overlap‑weighted), as abnormal returns — market beta stripped, so it's the event's own effect, not the market backdrop. Shown at 20 days (persistent) and 5 days (immediate); ↺ fades = the two horizons disagree. Confidence = consistency × sample × significance.

Wegovy 2021-06 First mRNA COVID-19 vaccine authorized 2020-12 Casgevy — first CRISPR gene-editing medicine approved 2023-12 mRNA pioneers win the Nobel 2023-10 First genetically-modified pig-to-human heart transplant 2022-01 AlphaFold cracks the protein-folding problem 2020-11 Human Genome Project completed 2003-04 Neuralink implants its first human brain-computer interface 2024-01 LK-99 room-temperature superconductor claim 2023-07 OpenAI releases GPT-4 2023-03 NIF achieves fusion ignition 2022-12 AlphaGo defeats Lee Sedol 2016-03 SpaceX lands an orbital rocket booster 2015-12
AssetHistory saysAbnormal (20d · 5d)HitnConfidencevs cascade
SOL SOLSHORT-9.2% · 5d -9.6%79%10 0.43⚠ differs
SPX SPXLONG+0.4% · 5d +1.0%66%13 0.29✓ matches cascade
US dollar DXYSHORT-0.6% · 5d -0.6%69%13 0.28·
Bitcoin BTCLONG+7.0% · 5d -5.3% ↺ fades62%12 0.23✓ matches cascade
High-yield credit HYGSHORT-0.1% · 5d -0.2%62%12 0.15·
SMH SMHLONG+0.8% · 5d +1.0%60%13 0.14✓ matches cascade
MSTR MSTRLONG+14.6% · 5d +0.1%57%13 0.13✓ matches cascade
Gold XAULONG+0.9% · 5d +0.2%57%13 0.11·
ETH ETHSHORT-2.5% · 5d -7.2%54%10 0.06⚠ differs
NDX NDXLONG+0.2% · 5d -0.4% ↺ fades54%13 0.06✓ matches cascade
10y yield DGS10LONG+4bp · 5d 0bp ↺ fades54%13 0.06·
XLK XLKLONG+0.7% · 5d +0.0%51%13 0.02✓ matches cascade
Volatility VIXLONG+2.7% · 5d -3.4% ↺ fades49%13 0.00⚠ differs
COIN COINLONG+2.6% · 5d -1.5% ↺ fades38%8 0.00✓ matches cascade

Methodology. Probability and impact are anchored to history and scored against what actually happens — wins and losses, in public, at Reality Check. Crowd odds live from Polymarket & Kalshi. By Vikas Singh, Quantitative Strategist. Updated 2026-07-03.